Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Chief Medical Officer | March 11, 2025 | March 13, 2025 |
| Forte Biosciences, Inc.TOCA · Entity 9529 | SVP Clinical Development | October 04, 2019 | October 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date March 11, 2025 · Filed March 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.58 · Expires 2035-03-11 | Direct | 780,008 |
Reported balance
After 2025-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-11 · Grant · Acquired 150,000 · Balance 780,008 F1: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 20,000 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2025 Filed Mar 13, 2025 20:06 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 150,000 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0000950170-25-038717 · ownership.xml · derivative · entry 1 Kabbinavar Fairooz · CIK 0001774182 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,008 Underlying: Common Stock · 150,000 shares Expires 2035-03-11 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 23:40 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 205,008 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001628280-24-009747 · wk-form4_1709854793.xml · derivative · entry 1 Kabbinavar Fairooz · CIK 0001774182 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630,008 Underlying: Common Stock · 205,008 shares Expires 2034-03-07 F1 · derivative.exercise_date: 25% of the shares subject to the option will vest on March 7, 2025 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person. Read SEC document |
| October 04, 2019 Filed Oct 5, 2019 00:36 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001209191-19-052621 · doc4.xml · derivative · entry 1 Kabbinavar Fairooz · CIK 0001774182 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:24 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $9.94 | $0.00 |
DisclosureSEC source: 0001209191-19-024982 · doc4.xml · derivative · entry 1 Kabbinavar Fairooz · CIK 0001774182 · SVP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/15/2019; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/15/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.